Dojindo Laboratories

Bloom Technology, Inc.

Kyoto University

Mochida Pharmaceutical Co., Ltd.

Daiichi Pure Chemicals Co., Ltd.

Fukuoka Prefectural Government

Dojindo Laboratories Co., Ltd.

Kazumi Sasamoto

Masanobu Shiga

Munetaka Ishiyama

Tetsuro Yamamoto

Mami Chirifu

Tomoaki Shigeta

Shota Tsuchida

Hiroshi Maeda

Hiroshi Mochizuki

Masahiro Nobuhara

Takaaki Akaike

Masayuki Nozawa

Itaru Hamachi

Makoto Mizoguchi

Susumu Ito

Chizu Ikeda

Takeshi Ido

Yoko Miyazono

Satoko Yamashita

Daikichi Horiguchi

Ryusuke Tsunoda

Kenichi Kusumoto

Rieko Kuroda

Ken Okumura

Keizo Sato

Tomoyuki Ishikawa

Yoshiki Katayama

Tetsuyuki Akao

Hiroshi Takeuchi

Kazuhiro Takesako

Takahiro Nagata

The present invention is directed to providing a monoclonal antibody having high selectivity and affinity for AGEs, particularly, AGEs derived from glyceraldehyde or AGEs derived from glycolaldehyde, and an analysis method utilizing the same. Another object of the present invention is to provide methods for diagnosing, treating and preventing a disease using the monoclonal antibody.

Antibody against advanced glycation end products and use thereof

The present invention provides a carrier capable of highly efficiently introducing a compound into cells with low cytotoxicity, which contains peptide lipids represented by the following formula, and a method for introducing a compound into cells using the carrier: wherein Ris an amino acid or peptide having 1-10 amino acid residues, Ris a side chain of any amino acid, provided that Rhas a carboxyl group, the carboxyl group may be an ester with a hydrocarbon group having 1-30 carbon atoms, Ris a hydrocarbon group having 1-30 carbon atoms. 

Peptide lipid-containing carrier and method for introducing compound into cells using same

Water-soluble tetrazolium salt compounds

Diagnostic marker

An object of the present invention is to inhibit the influence of the reducing substances on the oxidative coloring reaction in biological components. A constitution of the present invention is that a compound having the free radical of the general formula (1) ##STR1## is previously added to the biological sample and then an incubation is carried out. An effect of the present invention is that the influence of the reducing substances on the oxidation reaction can be inhibited and, even when no reducing substance is present, there is no effect on the oxidation reaction.

Method of inhibiting the activity of the reducing substances in

This invention offers the compounds which exhibit a coronary blood vessel dilating action which is long-acting. (Constitution) Novel imidazolinoxyl derivatives represented by a general formula (1). A compound A in which R is COOH is given in an example. ##STR1## (Merit) The compounds of the present invention can be directly administered, after diluting to a suitable concentration with a phosphate buffer or the like, to blood vessel which is required to be relaxed and dilated whereby a significant and long-acting relaxing action is resulted though, in a blood flow, they are quickly inactivated and excreted and no side effect is noted.

Imidazolinoxyl derivatives

A fluorescent compound, which is readily capable of forming a stable complex with a rare-earth metal ion having fluorescence with satisfactory intensity even in an aqueous system and long fluorescence lifetime when formed a complex with the rare-earth metal ion, a complex of the fluorescent compound and the rare-earth metal ion, and a labelled reagent made therefrom, together with a specific binding assay using said labelling agent. A fluorescent compound expressed by the following formula A, typically exemplified by 2,15-diaza[3,3](2,9)-1,10-phenanthrolinophane-N.sup.2,N.sup.15 -diacetic acid. ##STR1##

Fluorescent compound, complex, reagent, and specific binding assay

Growing community of inventors

Kumamoto, Japan

Kazumi Sasamoto